Kiniksa (KNSA) PT Raised to $44 at JMP Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Wall St set to open higher as jobs data dampens rate hike odds, yields fall
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
Kiniksa Presents KPL-716 Clinical Data at the 27th European Academy of Dermatology and Venereology
September 15, 2018 8:00 AM EDT- Single-doses were well-tolerated and showed reduction in pruritus -
- Data support plans for advancement into multiple chronic pruritic diseases, including prurigo nodularis -
HAMILTON, BERMUDA, Sept. 15, 2018 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today presented... More
Kiniksa Presents KPL-716 Clinical Data at the 27th European Academy of Dermatology and Venereology
September 15, 2018 8:00 AM EDT- Single-doses were well-tolerated and showed reduction in pruritus -
- Data support plans for advancement into multiple chronic pruritic diseases, including prurigo nodularis -
HAMILTON, BERMUDA, Sept. 15, 2018 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today presented Phase 1a/1b... More
